Rare-38. novel targets in ependymal tumors

CONCLUSIONS:If predicated on tumor expression, our data suggest that therapeutics directed toward ERCC1, ALK, PTEN, TOPO1, EGFR, TUBB3, and RRM1 could be considered for conventional treatment-refractory ependymal tumor patients.

Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Sanai, N., Xiu, J., Kim, L., Kesari, S., Zhou, S., Groot, J. d., Heimberger, A. Tags: RARE TUMORS Source Type: research